858474-14-3

Usage

Uses

Used in Cancer Treatment:
2-(4-Methoxyphenyl)-α-2-piperidinyl-4-quinolinemethanol Dihydrochloride is used as an inhibitor of P-glycoprotein (P-gp) for countering and reversing multi-drug resistance (MDR1) in patients diagnosed with cancer. It helps to resensitize paclitaxel-resistant cancer cells to paclitaxel, increasing the intracellular accumulation of P-gp substrates and preventing paclitaxel-induced overexpression of the P-gp gene MDR1 and P-gp protein level increases.
Used in Pharmaceutical Industry:
2-(4-Methoxyphenyl)-α-2-piperidinyl-4-quinolinemethanol Dihydrochloride is used as a research compound for studying the mechanisms of multidrug resistance in cancer cells and developing new strategies to overcome this resistance. It can be used in combination with other chemotherapeutic drugs to enhance their efficacy and overcome drug resistance in cancer treatment.

Upstream product

• 1369590-97-5 (2-(4-methoxyphenyl)quinolin-4-yl)(pyridin-2-yl)methanone 
• 1369590-98-6 (2-(4-methoxyphenyl)quinolin-4-yl)(pyridin-2-yl)methanol 
• 1384275-34-6 threo-tert-butyl 2-(hydroxy(2-(4-methoxyphenyl)quinolin-4-yl)methyl)piperidine-1-carboxylate 
• 4364-02-7 2-(4-methoxyphenyl)quinoline-4-carboxylic acid 
• 19287-55-9 (2-(4-methoxyphenyl)quinolin-4-yl)-(piperidin-2-yl)methanol 
• 91-56-5 indole-2,3-dione 
• 51842-72-9 methyl 2-(4-methoxyphenyl)quinoline-4-carboxylate 
• 100-06-1 1-(4-methoxyphenyl)ethanone 
• 1384275-41-5 erythro-tert-butyl 2-(hydroxy(2-(4-methoxyphenyl)quinolin-4-yl)methyl)piperidine-1-carboxylate 
• 1384275-32-4 C₂₇H₃₂N₂O₄ 
• 75844-69-8 t-butyl piperidinecarboxylate 
• 803640-64-4 2-(4-Methoxy-phenyl)-quinoline-4-carbonyl chloride 

Relevant academic research and scientific papers

Development of novel Asf1-H3/H4 inhibitors

The histone chaperone anti-silencing function 1 (Asf1) has emerged as a promising target for therapeutic intervention for multiple cancers (Cell 2006, 127, 458). Asf1 is involved in the packaging of the eukaryotic genome into chromatin, which is essential

IDENTIFICATION OF NSC23925 ISOMERS TO REVERSE MULTIDRUG RESISTANCE IN HUMAN CANCERS

This disclosure features optically active stereoisomers of (2-(4-methoxy)quinolin-4-yl)(piperidin-2-yl)methanol that reduce drug resistance, compositions containing the same, and methods of using and preparing the same.

Synthesis and evaluation of (2-(4-methoxyphenyl)-4-quinolinyl)(2- piperidinyl)methanol (NSC23925) isomers to reverse multidrug resistance in cancer

Development of multidrug resistance (MDR) during chemotherapy is a fundamental obstacle associated with cancer care. Prior studies have identified (2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (5) (NSC23925) to be a small molecule agent that r